S'abonner

Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996 - 24/04/13

Doi : 10.1016/j.jaad.2007.10.648 
Jeffrey S. Schneider, MD a, b, , Dan H. Moore, PhD b, c, Mortimer L. Mendelsohn, MD, PhD b
a Department of Dermatology, Kaiser Permanente Medical Center, San Rafael, California 
b Biomedical Sciences Division, Lawrence Livermore National Laboratory, Livermore, California 
c Research Institute, California Pacific Medical Center, San Francisco, California 

Reprint requests: Jeffrey Schneider, MD, Kaiser Permanente Medical Center, 99 Montecillo Road, San Rafael, CA 94903.

Abstract

Background

Worldwide incidence of cutaneous malignant melanoma has increased substantially, and no screening program has yet shown reduction in mortality. We evaluated results of an educational campaign designed to promote self-examination and targeted screening at the Lawrence Livermore National Laboratory (LLNL).

Methods

Thickness and crude incidence of melanomas detected during 3 phases of increasing melanoma surveillance were studied. These periods were: (1) preawareness (1969-1975), (2) early awareness of increased melanoma risk (1976-1984); and (3) screening program (1984-1996). Melanoma mortality was derived from data recorded in the National Death Index search. The expected annual number of deaths from melanoma among LLNL employees was calculated by using California mortality data matched by age, sex, and race/ethnicity and adjusted to exclude deaths from melanoma diagnosed before the program began or before employment at LLNL.

Results

Crude incidence of melanomas thicker than 0.75 mm decreased during the 3 periods from 22.1 to 15.13 to 4.62 cases per 100,000 person-years (P = .001 by chi-square for trend) with the larger decrease from the active screening program. The crude incidence of melanoma measuring less than 0.75 mm in thickness increased and then decreased slightly without a significant linear trend, and crude incidence of in situ melanoma increased substantially. No eligible melanoma deaths occurred among LLNL employees during the screening period, whereas the expected number of deaths was calculated to be 3.39 deaths (P = .034).

Limitations

The study design was not randomized or controlled. The methodology for adjusting expected mortality for the exclusion of employees diagnosed with melanoma before the screening period was devised for this study.

Discussion

Increasing community awareness of melanoma was associated with a progressive decreasing incidence of thicker melanoma. The education, self-examination, and selective program generated the larger reduction in incidence of melanoma thicker than 0.75 mm. This campaign decreased the melanoma-related mortality to zero. The statistically significant decrease in mortality persisted for at least 3 years after employees retired or otherwise left the laboratory.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : LLNL, NIH, NDI, SEER


Plan


 Research support, including travel, was provided by the US Department of Energy, which had no role in the study design. The Kaiser Foundation Research Institute provided a grant 139-9858 for partial salary support from 1994 to 1997.
 Conflicts of interest: None declared.


© 2008  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 58 - N° 5

P. 741-749 - mai 2008 Retour au numéro
Article précédent Article précédent
  • The spectrum of laser skin resurfacing: Nonablative, fractional, and ablative laser resurfacing
  • Macrene R. Alexiades-Armenakas, Jeffrey S. Dover, Kenneth A. Arndt
| Article suivant Article suivant
  • Notice to authors: New editor and new journal location begin June 1, 2008

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.